New treatment approved for deadly blood cancer
(HealthDay)—The U.S. Food and Drug Adminstration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL).
Aug 17, 2017
0
2
(HealthDay)—The U.S. Food and Drug Adminstration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL).
Aug 17, 2017
0
2
(HealthDay)—The combination chemotherapy drug Vyxeos (daunorubicin and cytarabine) has been approved by the U.S. Food and Drug Administration as the first treatment for certain high-risk types of acute myeloid leukemia ...
Aug 3, 2017
0
2
(HealthDay)—Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML).
Aug 1, 2017
0
0
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept ...
Jun 28, 2017
0
4
A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania ...
Jun 21, 2017
0
0
Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies. An existing drug might be repurposed to treat these leukemias, and the new understanding ...
Jun 14, 2017
0
0
Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. The blood cancer can affect both children and adults. Scientists have found up to 30 percent of ...
Jun 9, 2017
0
24
Physicians paid by pharmaceutical companies for meals, talks and travel had higher odds of prescribing those companies' drugs to treat two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led ...
Jun 1, 2017
0
1
(HealthDay)—Rydapt (midostaurin) has been approved by the U.S. Food and Drug Administration, in combination with chemotherapy, to treat adults with acute myeloid leukemia (AML) who have a specific genetic mutation dubbed ...
Apr 28, 2017
0
0
Drug compounds being developed at Purdue University could effectively target and inhibit protein kinase enzymes and secondary mutated versions that drive multiple types of cancers. The compounds are non-toxic compared to ...
Apr 25, 2017
0
82